Instinct Brothers Co., Ltd, a Japanese Vertically Integrated Regenerative Medicine & Stem Cell Technology Company, to Go Public via Merger with Relativity Acquisition Corp.
Instinct Brothers, a Japanese regenerative medicine and stem cell technology company, has announced a merger with Relativity Acquisition Corp to become publicly traded as Instinct Bio Technical Company (NASDAQ: BIOT). The combined entity will have an implied pro-forma enterprise value of $242 million.
The company operates a vertically integrated platform encompassing stem cell-based cosmeceuticals, R&D, manufacturing, and clinical applications through its GENREVER Clinic franchise. Their key asset is a high-quality stem cell culture medium containing over 380 cytokines and growth factors. The company owns ARTISANS PRODUCTION, an ISO 9001-certified manufacturing facility for cosmeceuticals and medical-grade regenerative products.
The transaction is expected to close in Q3 2025, subject to stockholder approval. Post-merger, current management led by founder Tomoki Nagano will continue running the combined company, with plans to expand clinics in Japan and enter markets in Malaysia and Indonesia.
Instinct Brothers, un'azienda giapponese specializzata in medicina rigenerativa e tecnologia delle cellule staminali, ha annunciato una fusione con Relativity Acquisition Corp per diventare quotata in borsa come Instinct Bio Technical Company (NASDAQ: BIOT). L'entità combinata avrà un valore d'impresa pro-forma implicito di 242 milioni di dollari.
L'azienda opera su una piattaforma verticalmente integrata che comprende cosmeceutici a base di cellule staminali, R&S, produzione e applicazioni cliniche attraverso la sua franchigia GENREVER Clinic. Il loro asset principale è un mezzo di coltura per cellule staminali di alta qualità contenente oltre 380 citochine e fattori di crescita. L'azienda possiede ARTISANS PRODUCTION, un impianto di produzione certificato ISO 9001 per cosmeceutici e prodotti rigenerativi di grado medico.
La transazione è prevista per chiudersi nel Q3 2025, soggetta all'approvazione degli azionisti. Dopo la fusione, l'attuale management guidato dal fondatore Tomoki Nagano continuerà a gestire l'azienda combinata, con piani per espandere le cliniche in Giappone e entrare nei mercati della Malesia e dell'Indonesia.
Instinct Brothers, una empresa japonesa de medicina regenerativa y tecnología de células madre, ha anunciado una fusión con Relativity Acquisition Corp para convertirse en una empresa cotizada como Instinct Bio Technical Company (NASDAQ: BIOT). La entidad combinada tendrá un valor empresarial pro forma implícito de 242 millones de dólares.
La empresa opera una plataforma verticalmente integrada que abarca cosmeceuticos a base de células madre, I+D, fabricación y aplicaciones clínicas a través de su franquicia GENREVER Clinic. Su activo clave es un medio de cultivo de células madre de alta calidad que contiene más de 380 citoquinas y factores de crecimiento. La empresa posee ARTISANS PRODUCTION, una instalación de fabricación certificada ISO 9001 para cosmeceuticos y productos regenerativos de grado médico.
Se espera que la transacción se cierre en Q3 2025, sujeta a la aprobación de los accionistas. Después de la fusión, la gestión actual liderada por el fundador Tomoki Nagano continuará dirigiendo la empresa combinada, con planes para expandir clínicas en Japón e ingresar a los mercados de Malasia e Indonesia.
Instinct Brothers는 일본의 재생 의학 및 줄기 세포 기술 회사로, Relativity Acquisition Corp와 합병하여 Instinct Bio Technical Company (NASDAQ: BIOT)로 상장될 것이라고 발표했습니다. 합병된 기업의 암시적 프로포르마 기업 가치는 2억 4천 2백만 달러에 달할 것입니다.
이 회사는 줄기 세포 기반의 코스메슈티컬, 연구개발, 제조 및 임상 응용을 포함하는 수직적으로 통합된 플랫폼을 운영하고 있으며, GENREVER Clinic 프랜차이즈를 통해 이를 실현하고 있습니다. 그들의 주요 자산은 380개 이상의 사이토카인과 성장 인자를 포함하는 고품질 줄기 세포 배양 매체입니다. 이 회사는 코스메슈티컬 및 의료용 재생 제품을 위한 ISO 9001 인증 제조 시설인 ARTISANS PRODUCTION을 소유하고 있습니다.
거래는 2025년 3분기에 종료될 것으로 예상되며, 주주 승인에 따라 달라질 수 있습니다. 합병 후, 설립자인 토모키 나가노가 이끄는 현재 경영진이 합병된 회사를 계속 운영할 예정이며, 일본 내 클리닉을 확장하고 말레이시아 및 인도네시아 시장에 진출할 계획입니다.
Instinct Brothers, une entreprise japonaise spécialisée dans la médecine régénérative et la technologie des cellules souches, a annoncé une fusion avec Relativity Acquisition Corp pour devenir cotée en bourse sous le nom de Instinct Bio Technical Company (NASDAQ: BIOT). L'entité combinée aura une valeur d'entreprise pro forma implicite de 242 millions de dollars.
L'entreprise opère une plateforme intégrée verticalement englobant des cosméceutiques à base de cellules souches, de la R&D, de la fabrication et des applications cliniques à travers sa franchise GENREVER Clinic. Leur actif clé est un milieu de culture de cellules souches de haute qualité contenant plus de 380 cytokines et facteurs de croissance. L'entreprise possède ARTISANS PRODUCTION, une installation de fabrication certifiée ISO 9001 pour des cosméceutiques et des produits régénératifs de qualité médicale.
La transaction devrait être finalisée au Q3 2025, sous réserve de l'approbation des actionnaires. Après la fusion, l'équipe de direction actuelle dirigée par le fondateur Tomoki Nagano continuera à diriger l'entreprise combinée, avec des projets d'expansion des cliniques au Japon et d'entrée sur les marchés de Malaisie et d'Indonésie.
Instinct Brothers, ein japanisches Unternehmen für regenerative Medizin und Stammzelltechnologie, hat eine Fusion mit Relativity Acquisition Corp angekündigt, um als Instinct Bio Technical Company (NASDAQ: BIOT) an die Börse zu gehen. Das kombinierte Unternehmen wird einen implizierten pro forma Unternehmenswert von 242 Millionen Dollar haben.
Das Unternehmen betreibt eine vertikal integrierte Plattform, die Stammzell-basierte Kosmetika, F&E, Produktion und klinische Anwendungen über sein GENREVER Clinic-Franchise umfasst. Ihr Hauptvermögen ist ein hochwertiges Stammzellkulturmedium, das über 380 Zytokine und Wachstumsfaktoren enthält. Das Unternehmen besitzt ARTISANS PRODUCTION, eine nach ISO 9001 zertifizierte Produktionsstätte für Kosmetika und medizinische regenerative Produkte.
Die Transaktion wird voraussichtlich im Q3 2025 abgeschlossen, vorbehaltlich der Genehmigung der Aktionäre. Nach der Fusion wird das aktuelle Management unter der Leitung von Gründer Tomoki Nagano das kombinierte Unternehmen weiterhin führen und plant, die Kliniken in Japan auszubauen und in die Märkte von Malaysia und Indonesien einzutreten.
- Vertical integration across stem cell research, manufacturing, and clinical applications
- ISO 9001-certified manufacturing facility ensures quality control
- Proprietary stem cell culture medium with 380+ cytokines
- Clear expansion strategy into Malaysia and Indonesia markets
- Access to public capital markets to fund growth
- Subject to stockholder approval and closing conditions
- Potential redemptions by SPAC shareholders could affect valuation
- Execution risk in planned international expansion
- Complex integration process of multiple affiliated entities
Insights
This SPAC merger represents a strategic market entry for Instinct Brothers, providing public market access without traditional IPO complexities. The $242 million enterprise valuation positions the combined entity as a mid-cap player in the regenerative medicine space. The transaction structure merits careful analysis, particularly regarding potential dilution for existing Relativity shareholders.
Instinct Brothers' vertically integrated business model creates multiple revenue streams - cosmeceuticals provide near-term commercialization while clinical applications represent longer-term growth potential. This diversification reduces single-segment risk exposure common in biotech. Their ISO 9001-certified manufacturing capability is particularly valuable in cell therapy, where production quality and scalability often become bottlenecks.
Investors should note the extended closing timeline (Q3 2025), suggesting regulatory reviews and shareholder approvals may be complex. The article lacks critical financial metrics - revenue figures, growth rates, gross margins, and cash runway details are absent, making valuation assessment challenging. The planned expansion into Malaysia and Indonesia introduces new market opportunities but adds regulatory complexity and execution risk.
The transaction appears structured to provide Instinct Brothers with capital for global expansion and clinical development while giving Relativity shareholders exposure to regenerative medicine. However, without specific financial performance data, it's difficult to fully assess if the $242 million valuation represents fair value relative to comparable companies in this sector.
Instinct Brothers has strategically positioned itself in the regenerative medicine landscape through vertical integration spanning research, manufacturing, and clinical applications. Their proprietary stem cell culture medium containing over 380 cytokines and growth factors suggests a comprehensive approach to cellular nutrition and stimulation, potentially offering advantages in cellular vitality and therapeutic potency.
The GENREVER Clinic franchise model represents an innovative approach to commercializing regenerative therapies, focusing on anti-aging, immune support, and disease prevention. This model could enable standardized protocols and quality control across multiple locations while accelerating market penetration. However, the article lacks details on specific therapeutic indications, clinical validation data, and regulatory approvals for their stem cell applications.
Owning an ISO 9001-certified manufacturing facility provides important quality control capabilities essential for cell-based products, where manufacturing consistency directly impacts clinical outcomes. This infrastructure reduces reliance on contract manufacturers and enhances intellectual property protection.
The planned Cell Processing Center joint venture suggests movement toward more advanced therapeutic applications beyond cosmeceuticals. This balanced approach - generating revenue from consumer products while developing medical applications - represents a pragmatic strategy in regenerative medicine where regulatory pathways can be lengthy.
The company appears focused primarily on perinatal stem cells, which offer immunological advantages and differentiation potential compared to adult stem cells. Their expansion plans into Southeast Asian markets align with regional regulatory environments that have sometimes moved faster than Western markets in approving certain regenerative therapies.
- Instinct Brothers Co., Ltd has entered into a definitive business combination agreement with Relativity Acquisition Corp.
- The combined company, to be named Instinct Bio Technical Company Inc., will have an implied pro-form enterprise value of approximately
$242 million , assuming no further redemptions by Relativity’s public stockholders prior to the closing of the business combination.
NEW YORK, NY, TOKYO, JAPAN, March 04, 2025 (GLOBE NEWSWIRE) -- Instinct Brothers Co., Ltd., along with its affiliated entities—Hiroki Global Co., Ltd, Artisans Production Co., Ltd, Instinct RAS Co., Ltd (collectively, “Instinct Brothers” or the “Company”)—a vertically integrated regenerative medicine and stem cell technology company based in Japan, and Relativity Acquisition Corp. (“Relativity”), a special purpose acquisition company, today announced that they have entered into a definitive business combination agreement (the “Merger Agreement”) that will result in Instinct Brothers becoming a wholly-owned subsidiary of Relatively upon the closing of the transaction contemplated therein (the “Proposed Transaction”) in accordance with the terms and conditions in the Merger Agreement.
Upon closing the Proposed Transaction, the combined company will operate under the name Instinct Bio Technical Company Inc. (the “Combined Company”) and intends to list on the NASDAQ Stock Exchange under the ticker symbol ‘BIOT’.
A Pioneering, Vertically Integrated Platform for Regenerative Medicine
With a mission to harness the transformative power of stem cell science, Instinct Brothers has built an ecosystem that integrates stem-cell-based cosmeceuticals, research and development, university partnerships, proprietary manufacturing, industry-leading alliances, global distribution, branding, direct-to-consumer retail, medical consulting and total coordination service for franchise medical clinics, and clinical application research in regenerative medicine.
By leveraging a high-quality stem cell culture medium with over 380 cytokines and growth factors, Instinct Brothers has positioned itself in the field of stem cell-derived skincare. Through its franchise GENREVER Clinic, the Company has developed a structured model for stem cell-based regenerative therapies targeting anti-aging, immune support, regenerative treatments, and disease prevention.
Additionally, Instinct Brothers owns and operates ARTISANS PRODUCTION CO., LTD, an ISO 9001-certified manufacturing facility, allowing for seamless production of cosmeceuticals and medical-grade regenerative products. This facility enables precision manufacturing, stringent quality control, and continuous innovation, reinforcing Instinct Brothers' commitment to excellence in stem cell technology and regenerative medicine.
The Instinct Brothers management team, led by its founder Tomoki Nagano, will continue to run the Combined Company after the closing of the Proposed Transaction.
Tomoki Nagano, Group Chairman and Chief Executive Officer of Instinct Brothers, said:
"This transaction marks a transformational milestone for Instinct Brothers, positioning us to accelerate our global expansion and enhance access to cutting-edge stem cell-based therapies. Going public will allow us to scale our operations, broaden our clinical footprint, and fuel the development of new regenerative treatments that improve health and longevity. We are committed to bringing life-changing solutions to a global audience with plans to expand our clinic model into Malaysia and Indonesia, construct new clinics in Japan, and advance our Cell Processing Center joint venture."
Tarek Tabsh, Chief Executive Officer of Relativity Acquisition Corp., commented:
"Perinatal stem cells have an intrinsic capacity to repair and regenerate targeted tissues, and unique adaptability that makes them a promising frontier for regenerative medicine application potential. Instinct Brothers has built a well-integrated business that delivers scientific innovation from the bench to the bedside. Their vertically integrated platform, spanning research, manufacturing, distribution, retail, and clinical application, positions them uniquely for expansion into adjacent markets. We are excited to support their journey as they continue to deliver the next generation of regenerative medicine."
Transaction Overview
Under the terms of the Merger Agreement, Relativity will acquire all issued and outstanding shares of Instinct Brothers, making it a wholly owned subsidiary of Relativity. As part of the Proposed Transaction, Instinct Brothers will become a publicly traded entity under the name “Instinct Bio Technical Company Inc.” The Proposed Transaction values the Combined Company at an estimated pro forma enterprise value of approximately
Advisors
Chardan Capital Markets LLC is the exclusive M&A and Capital Markets advisor to Instinct Brothers Holdings. Darryl, Edward & Co. is a legal advisor for Instinct Brothers Holdings.
Loeb & Loeb LLP and Barnett & Linn LLP serve as legal advisors to Relativity Acquisition Corp.
About Instinct Brothers
Instinct Brothers is a vertically integrated Japanese company specializing in stem cell technology and regenerative medicine, encompassing research and development, manufacturing, distribution, retail, and clinical applications. Founded in 2017, Instinct Brothers is led by industry expert Tomoki Nagano, Group Chairman and Chief Executive Officer, an industry expert with a vision to drive innovation in regenerative medicine. The Company’s mission is to advance stem cell science, enhance patient outcomes, and pioneer the next generation of stem cell-based therapies.
About Relativity Acquisition Corp.
Relativity Acquisition Corp. is a blank check company sponsored by Relativity Acquisition Sponsor LLC, a Delaware limited liability company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
Additional Information and Where to Find It
In connection with the Proposed Transaction, Relativity and Instinct Brothers intends to file a Registration Statement on Form F-4 (the “Form F-4”) with the United States Securities and Exchange Commission ( the “SEC”), which will include a preliminary prospectus with respect to its securities to be issued in connection with the Proposed Transaction and a preliminary proxy statement with regard to Relativity’s stockholder meeting at which Relativity’s stockholders will be asked to vote on the Proposed Transaction. Relativity’s investors, stockholders and other interested persons are advised to read, when available, the Form F-4, including the proxy statement/prospectus, any amendments thereto and any other documents filed with the SEC, because these documents will contain important information about the proposed business combination. After the Form F-4 has been filed and declared effective, Relativity will mail the definitive proxy statement/prospectus to stockholders of Relativity as of a record date to be established for voting on the business combination. Relativity stockholders will also be able to obtain a copy of such documents, without charge, by directing a request to: Relativity Acquisition Corp., 3753 Howard Hughes Parkway, Suite 200 Las Vegas, Nevada 89169; e-mail: info@relativityacquisitions.com. These documents, once available, can also be obtained, without charge, at the SEC’s website www.sec.gov.
Participants in the Solicitation
Relativity and its directors and officers may be deemed participants in soliciting proxies of Relativity’s stockholders in connection with the proposed business combination. Security holders may obtain more detailed information regarding the names, affiliations and interests of certain of Relativity’s executive officers and directors in the solicitation by reading Relativity’s final prospectus filed with the SEC on February 14, 2022, the proxy statement/prospectus and other relevant materials filed with the SEC in connection with the business combination when they become available. Information concerning the interests of Relativity’s participants in the solicitation, which may, in some cases, be different from those of their stockholders generally, will be set forth in the proxy statement/prospectus relating to the business combination when it becomes available.
No Offer or Solicitation
This press release does not constitute an offer to sell or a solicitation of an offer to buy, or the solicitation of any vote or approval in any jurisdiction in connection with a proposed potential business combination among Relativity and Instinct Brothers or any related transactions, nor shall there be any sale, issuance or transfer of securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful. Any offering of securities or solicitation of votes regarding the proposed transaction will be made only by means of a proxy statement/prospectus that complies with applicable rules and regulations promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and Securities Exchange Act of 1934, as amended, or pursuant to an exemption from the Securities Act or in a transaction not subject to the registration requirements of the Securities Act.
Forward Looking Statements
This press release may include, and oral statements made from time to time by representatives of the Company may include “forward-looking statements”. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release, are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Form F-4 and prospectus to be filed with the SEC. The Company and Relativity undertake no obligation to update these statements for revisions or changes after the date of this release except as required by law.
Contact Information
Instinct Brothers Co., Ltd.
Email: ir@instinct-biot.com
Website: https://instinct-bro.com/
Relativity Acquisition Corp.
Email: info@relativityacquisitions.com
Website: www.relativityacquisitions.com
FAQ
What is the expected enterprise value of BIOT after the merger with Relativity Acquisition Corp?
When will Instinct Brothers (BIOT) begin trading on NASDAQ?
What are the main business segments of Instinct Brothers (BIOT)?
What are Instinct Brothers' (BIOT) expansion plans post-merger?
